NapaJen Pharma Inc.
http://www.napajen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NapaJen Pharma Inc.
Asia Deal Watch: Zogenix Partners Japanese Rights To Pediatric Epilepsy Therapy To Nippon Shinyaku
Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.
Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Vaccines
- Other Names / Subsidiaries
-
- NapaJen Co Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice